Instituto de Investigaciones Clínicas Mar del Plata
Somos una organización que trabaja en la generación de conocimiento para mejorar la calidad de vida de las personas a través de la investigación clínica. Trabajamos con un fuerte interés en concientizar y educar a la sociedad sobre la prevención y tratamiento de enfermedades y sobre la importancia de los ensayos clínicos para lograrlo.Av. Colón 3456, Mar del Plata, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de pulmón
Diabetes
Obesidad
Taquicardia supraventricular paroxística
Hipertensión arterial pulmonar
Cáncer de próstata
Fibrosis pulmonar
Cáncer de útero
Cardiovascular
Cáncer de mama
Insuficiencia cardíaca
Cáncer de riñón
Enfermedad renal crónica
Patients Benefits
Refrigerio
Viáticos
Our team
Authorities
Médico clínico e investigador
Cardiovascular Research Department, Head & Co-FounderIgnacio Jorge MacKinnon
Medical staff
Médico especialista en oncología 
Médico clínico investigador
Médica investigadora 
Médico Especialista en Infectología
Médico clínico e investigador
Investigador PrincipalIgnacio Alfredo Casarini
Investigador PrincipalSergio Andrés Nemi
Investigadora PrincipalNatalia Cluigt
Investigador PrincipalGonzalo Corral
Investigador PrincipalPablo Martinez Monferrán
Investigador PrincipalPablo Corral
Sub-investigadora principalMicaela Leis
Investigadora PrincipalVirginia Laura Sernia
Legal and Administrative staff
Chief Operating OfficerClarisa De Luca
Jefa del departamento de reclutamientoPía Leone
Study coordinatorAriana Balcarce
Open studies
Cardiovascular disease
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease - VICTORION-2P - Novartis PharmaceuticalsSee more
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. - VICTORION 1 - Novartis PharmaceuticalsSee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Kidney cancer
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread - CheckMate-67T - Bristol-Myers SquibbSee more
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma - STELLAR-304 - ExelixisSee more
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Lung cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
Chronic obstructive pulmonary disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD - TRITON - Chiesi Farmaceutici S.p.A.See more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body - STAR-221 - Arcus Biosciences, Inc.See more
Hypercholesterolemia
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease - VICTORION-2P - Novartis PharmaceuticalsSee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Obesity
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
Prostate cancer
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) - MK-3475-641 - Merck Sharp & Dohme Corp.See more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - MK-5684-003 - Merck Sharp & Dohme LLCSee more
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Chronic bronchitis
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor - Novo Nordisk A/SSee more
Gastric cancer
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body - STAR-221 - Arcus Biosciences, Inc.See more
Gastroesophageal cancer
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body - STAR-221 - Arcus Biosciences, Inc.See more
Heart failure
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/SSee more
Inflammation
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/SSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Pulmonary hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients - APD811-301 - United TherapeuticsSee more
Skin cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
